Great Point Partners LLC Macrogenics Inc Transaction History

Great Point Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$8.12 - $16.9 $8.12 Million - $16.9 Million	-1,000,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$19.74 - $28.7 $7.47 Million - $10.9 Million	-378,495 Reduced 27.46%	1,000,000 $20.9 Million
Q2 2021 Aug 16, 2021	BUY	$20.49 - $35.63 $583,862 - $1.02 Million	28,495 Added 2.11%	1,378,495 $37 Million
Q1 2021 May 17, 2021	BUY	$18.99 - $33.2 $2.1 Million - $3.68 Million	110,713 Added 8.93%	1,350,000 $43 Million
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $5.26 Million - $7.04 Million	-270,928 Reduced 17.94%	1,239,287 $28.3 Million
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $252,208 - $322,794	10,215 Added 0.68%	1,510,215 $38 Million
Q2 2020 Aug 14, 2020	BUY	$5.2 - $29.12 $7.8 Million - $43.7 Million	1,500,000 New	1,500,000 $41.9 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $202M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.